Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

BACKGROUND: ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Proteomics
Main Authors: Couëtoux du Tertre, Mathilde, Marques, Maud, McNamara, Suzan, Gambaro, Karen, Hoffert, Cyrla, Tremblay, Lise, Bouchard, Nicole, Diaconescu, Razvan, Blais, Normand, Couture, Christian, Pelsser, Vincent, Wang, Hangjun, McIntosh, Laura, Hindie, Valérie, Parent, Stephane, Cortes, Laetitia, Breton, Yannick-André, Pottiez, Gwenael, Croteau, Pascal, Higenell, Valerie, Izzi, Luisa, Spatz, Alan, Cohen, Victor, Batist, Gerald, Agulnik, Jason
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2020
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006423/
https://ncbi.nlm.nih.gov/pubmed/32055239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12014-020-9269-6
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים